Mesothelioma

Smoking negatively affects many organs and gradually worsens health, especially lung function. It causes mild airway obstruction and slows lung growth, impacting breathing and overall quality of life. This study evaluates balloon-blowing exercises combined with abdominal and lumbar core muscle activation positions to see if they can improve lung function and quality of life in smokers. Participants will be randomly assigned to one of two groups: one will perform balloon-blowing exercises with abdominal and lumbar core muscle activation three times a week for four weeks, supervised by a physical therapist. The other group will perform diaphragmatic breathing exercises with the same frequency and duration. Both interventions last four weeks, with measurements taken before and after. Participants will undergo evaluations of lung function including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), dyspnea levels, oxygen saturation, and quality of life assessments. These measures will be collected at the start and end of the four-week period to monitor changes and effects of the exercises on respiratory health.

Researchers are evaluating a new PET imaging tracer called [18F]FAPI-74 to detect cancer by targeting the fibroblast-activation protein (FAP) found in cancer-associated fibroblasts. This study aims to compare [18F]FAPI-74 PET scans to the standard [18F]-FDG PET scans and other imaging methods like CT or MRI across several cancers including pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, gastric, bladder, ovarian cancers, pheochromocytoma/paraganglioma, small cell lung cancer, neuroendocrine cancer, mesothelioma, and sarcoma. The study is a phase 2 interventional trial conducted by the National Cancer Institute (NCI). Participants will receive an intravenous dose of [18F]FAPI-74 before undergoing PET/CT imaging about one hour later. They will also have a baseline FDG PET scan within one week. If tumors are detected by [18F]FAPI-74, additional scans using this tracer and FDG may be repeated during routine treatment and if cancer progresses within two years. Those with negative baseline [18F]FAPI-74 scans will not have repeated scans but remain in follow-up. The study involves a single arm where participants undergo both types of PET imaging. During the study, participants will have scans at baseline and potentially at subsequent treatment or progression points. Safety monitoring includes observation for reactions to the tracer up to three days after injection. Researchers will measure the mean number of lesions, standardized uptake values at baseline, post-treatment, and recurrence. Follow-up calls will continue for two years to assess progression-free survival and overall survival. The total participation duration includes imaging visits and two years of follow-up monitoring.

Researchers are evaluating a new preoperative method using three-dimensional CT scans and virtual resection simulation to predict lung function after surgery in patients with non-small cell lung cancer (NSCLC) undergoing Video-Assisted Thoracoscopic Surgery (VATS). This study aims to improve accuracy over traditional methods by accounting for differences in lung ventilation caused by tumors or emphysema. It is a prospective, multi-center, longitudinal cohort study involving 60 patients split evenly between those having lobectomy and segmentectomy. Participants will undergo detailed thin-slice chest CT scans and pulmonary function tests before surgery. Using Synapse 3-D software, doctors will create patient-specific 3-D lung models to simulate the planned lung tissue removal and calculate the fraction of ventilated lung to be resected. After surgery, patients will follow standard VATS procedures. The study includes long-term follow-up with pulmonary function tests at 3, 6, and 12 months and CT scans at 6 and 12 months to observe structural lung changes. During the study, participants will have preoperative assessments, surgery, and several postoperative visits for lung function tests and imaging. Researchers will measure how closely the predicted lung function matches actual results at 3 months, as well as longer-term accuracy at 6 and 12 months. They will also study how well the remaining lung compensates after surgery and the effect of any complications on recovery. The total participation spans about one year after surgery, allowing detailed evaluation of lung function and recovery.

Researchers are evaluating a new dual-target imaging agent called 68Ga-FAPI-RGD for PET/CT scans in patients with lung cancer. This agent targets both fibroblast activating protein (FAP) on tumor tissues and integrin b1vb23 receptors on blood vessels, aiming to improve visualization of lung cancer lesions. The study compares this novel agent with conventional 18F-FDG and single-target agents 68Ga-FAPI and 68Ga-RGD to overcome limitations of current imaging methods. Participants will receive intravenous injections of the imaging agents, including 68Ga-FAPI-RGD, 18F-FDG, 68Ga-FAPI, and 68Ga-RGD, at doses based on body weight. Each patient undergoes PET/CT scans within two weeks after receiving 68Ga-FAPI-RGD and one of the other agents. Three experimental groups compare 68Ga-FAPI-RGD with either 18F-FDG, 68Ga-FAPI, or 68Ga-RGD to assess diagnostic performance. During the study, participants will have PET/CT scans and monitoring for diagnostic accuracy over about one year. Researchers will evaluate the imaging agents' uptake at different times and radiation dosimetry. The trial includes assessments of lung cancer lesions using these agents to understand their ability to detect tumors effectively. Participants' safety and study compliance are monitored throughout the trial period.

Researchers are conducting an open-label, multi-site, multi-cohort phase 1/2 trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 combined with anti-cancer therapies in participants with advanced solid tumors, including mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer (NSCLC). The study aims to understand how ODM-212 works alongside other treatments in these serious cancers. The trial has two parts: dose escalation and dose expansion/optimization. Participants receive ODM-212 tablets along with other anti-cancer drugs depending on their cancer type. For mesothelioma, ODM-212 is combined with ipilimumab and nivolumab given intravenously on specific schedules. For pancreatic cancer, it is combined with gemcitabine and nab-paclitaxel administered intravenously in cycles. For NSCLC with a KRAS G12C mutation, ODM-212 is combined with sotorasib taken orally daily in 21-day cycles. Participants will be closely monitored throughout the study, with evaluations of side effects, dose-limiting toxicities, and adverse events tracked on average for two years. The research team will collect tumor tissue samples, monitor treatment adherence, and perform assessments to measure disease status and treatment effects. Safety will be carefully checked with exams, ECGs, and laboratory tests. The study is planned to continue through 2029, with ongoing visits and follow-ups as part of participant involvement.

Researchers are evaluating MDNA11, a long-acting "beta-only" recombinant interleukin-2 designed to activate immune cells that kill cancer while minimizing activation of immunosuppressive cells. This Phase 1/2 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of MDNA11 alone or combined with the checkpoint inhibitor pembrolizumab in patients with advanced solid tumors. The study is conducted at multiple sites with regulatory and ethical approvals and includes about 115 patients. The trial has several parts: dose escalation and expansion for MDNA11 monotherapy and for its combination with pembrolizumab. MDNA11 is given intravenously every two weeks with doses adjusted to find the recommended dose for expansion. Tumor assessments using CT or MRI scans happen every 8 weeks to monitor response until disease progression or other study-end criteria occur. Treatment may continue beyond progression under certain conditions. Participants undergo evaluations including tumor imaging, laboratory tests, and safety monitoring over up to 24 months. Researchers measure recommended dose levels, treatment-related adverse events, pharmacokinetics, immune response, and anti-tumor activity such as response rates and progression-free survival. Patients can withdraw anytime, and safety follow-up continues to understand MDNA11's effects alone and with pembrolizumab.

Researchers are evaluating the safety and effectiveness of CHT102, a universal chimeric antigen receptor T-cell immunotherapy (U CAR-T), in treating patients with mesothelin-positive advanced solid tumors. This study focuses on patients with advanced or metastatic solid tumors that express mesothelin and have not responded to standard first-line therapies or have no recommended first-line treatment options. The trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and aims to assess dose-related toxicities and treatment responses. The study includes a dose escalation phase where participants receive CHT102 allogeneic CAR T cells through multiple infusions. Treatment involves three transfusions of UCAR-T cells on days 1, 5, and 9 within a 28-day cycle. Different dose levels are tested, ranging from 2.5 x 10^6/kg to 3 x 10^7/kg of CAR-positive T cells per infusion, with dose increases between groups. This dose escalation helps determine the appropriate dosage for further evaluation. Participants will be closely monitored for safety, including the occurrence of dose-limiting toxicities up to 28 days after infusion. Researchers will also measure objective tumor response at 4 weeks and overall, as well as progression-free survival up to 6 months. The study involves regular assessments of organ function, tumor measurements by RECIST criteria, and evaluation of patient health status. Participants are expected to remain in the study for follow-up assessments as scheduled to evaluate treatment effects and safety.

Researchers are evaluating the drug NXP900 in people with advanced solid tumors, including specific genetic alterations affecting certain pathways related to cancer growth. This first-in-human Phase 1 study aims to understand how patients tolerate NXP900 and how their tumors respond to it. The study focuses on tumors with direct or dependent targets of the drug, such as YES1 amplification and Hippo Pathway alterations, to explore new treatment options for patients with limited therapies. The study has two parts: Part A involves escalating doses of NXP900 starting at 20 mg once daily to find a safe dose, while Part B expands the study to more participants receiving the selected dose. NXP900 is an oral drug taken once per day. Participants continue on their assigned doses while researchers monitor safety and effectiveness. The study is open label and non-randomized, meaning all participants know they are receiving NXP900 without a comparison placebo or alternative treatment. Participants will be involved in regular assessments including imaging scans to measure tumor size, clinical exams, laboratory tests, and monitoring for side effects. Researchers will track treatment-related adverse events, dose-limiting toxicities, and tumor response rates over periods up to 24 months. The study also measures how the drug is processed in the body through blood tests. Participation length varies depending on treatment response and safety, with follow-up extending up to two years to gather comprehensive data.

Researchers are evaluating the combination of Adebrelimab with carboplatin or cisplatin plus etoposide chemotherapy and concurrent radiotherapy as a first treatment for patients with extensive-stage oligometastatic small cell lung cancer. This Phase II open-label study aims to assess the safety and effectiveness of this regimen in this patient group. The trial is led by Nanfang Hospital, Southern Medical University and focuses on patients with limited metastatic lesions and organs affected. Participants will first receive Adebrelimab intravenously along with carboplatin or cisplatin and etoposide for two cycles during the induction phase. Next, participants undergo concurrent chemoradiotherapy, including thoracic radiation and stereotactic body radiation therapy (SBRT) to metastases, combined with one to two cycles of chemotherapy. Following this, they will receive one to two additional cycles of Adebrelimab combined with chemotherapy, and then continue on Adebrelimab alone as maintenance therapy until disease progression, unacceptable side effects, or withdrawal from the study. During the study, participants will be closely monitored through clinical assessments, imaging, and laboratory tests to track progression-free survival and other measures such as overall survival and response rates, with follow-up lasting up to approximately 30 months. Safety will be monitored by recording adverse events throughout the treatment and maintenance phases. The total participation time includes induction, concurrent chemoradiotherapy, maintenance, and follow-up periods to fully evaluate treatment outcomes and tolerability.

Researchers are evaluating the Integrative Medicine at Home (IM@Home) program to see if it improves patient-reported values, outcomes, and experiences for people undergoing systemic cancer treatments such as chemotherapy, immunotherapy, radiotherapy, targeted agents, or cytoreductive surgery. This program is part of the IMPROVE research initiative and focuses on patients with various cancers including head and neck, thoracic, gynecologic, melanoma, breast, and ovarian cancers. The goal is to assess how virtual mind-body therapies may support cancer patients during their treatment journey. Participants will be randomly assigned to either the IM@Home group or an enhanced usual care group. Those in the IM@Home group will take part in a 12-week virtual program offering weekly synchronous mind-body and fitness classes via Zoom, led by trained therapists with oncology expertise. Classes include activities such as fitness, yoga, dance therapy, tai chi, meditation, guided meditation, and music therapy. Each session lasts 30 to 45 minutes, with time for feedback and discussion. The enhanced usual care group will receive standard care plus access to pre-recorded meditation and relaxation resources. During the 12 weeks, participants will be monitored through patient-reported assessments measuring fatigue severity, symptom intensity, insomnia, psychological distress, pain, treatment expectancy, satisfaction, and session attendance. Researchers will also track treatment disruptions and unplanned medical visits. These evaluations will help determine the impact of the IM@Home program on patient well-being and treatment experience throughout the study period.